Midodrine

DEA Class;  Rx

Common Brand Names; ProAmatine, Orvaten

Severe organic heart disease, supine HTN, acute renal disease, urinary retention, pheochromocytoma, thyrotoxicosis

• Paresthesia (18%)
• Piloerection (13%)
• Pruritus (13%)
• Supine hypertension (7-13%)
• Urinary retention or urgency (up to 13%)
• Chills (5%)
• Pain, including abdominal pain (5%)
• Rash (2%)
• <1%
• Anxiety
• Canker sore
• Confusion
• Dizziness
• Dry skin
• Erythema multiforme
• Facial flushing
• Flushing
• Headache
• Hyperesthesia
• Insomnia
• Intracranial pressure increased
• Nausea
• Somnolence
• Weakness
• Xerostomia

May slow heart rate primarily due to vagal reflex; use caution when administering concomitantly with negative chronotropes, including digoxin, beta blockers, or other agents that decrease heart rate; discontinue use if signs or symptoms of bradycardia occur

Risk of hypertension increases with concomitant administration of drugs that increase blood pressure (phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, or droxidopa); avoid concomitant use of drugs that increase blood pressure; if concomitant use cannot be avoided, monitor blood pressure closely

Avoid concomitant administration with MAO inhibitors or linezolid

It is essential to monitor supine and sitting blood pressures in patients receiving therapy; uncontrolled hypertension increases risk of cardiovascular events, particularly stroke

Avoid concomitant use with treatment agents that may cause vasoconstriction

Use caution in patients with diabetes mellitus, vision problems, and renal or hepatic impairment

Take drug no later than 6 pm and 3-4 hr before bed to minimize supine HTN

Pregnancy category: C

Lactation: Not known if excreted into breast milk; avoid

Midodrine hydrochloride

tablet

• 2.5mg
• 5mg
• 10mg